An ultrasound apparatus of a body cavity insertable type includes: a handpiece; a supporting rod which is elongated from the handpiece; an ultrasound probe which is connected to the supporting rod and is configured to be able to be inserted in the body cavity; and a sealing cover which is separably coupled to the ultrasound probe to at least partially surround the ultrasound probe in a longitudinal direction from a distal end thereof. The ultrasound probe includes: a piezoelectric element; and a housing to which the piezoelectric element is mounted. An end of the housing is connected to the supporting, and the housing is provided with an ultrasound passing hole which is disposed outside the supporting rod. The sealing cover has an ultrasound passing window which is formed at a position corresponding to the ultrasound passing hole.

The invention relates to a tissue monitoring apparatus, a tissue monitoring method and an ablation lesion monitoring, measuring, and controlling automated algorithm incorporating diffuse reflectance spectroscopy (DRS) and/or Arrhenius model thermal denaturation kinetics for determining the characteristics of the lesion or the tissue, especially for identifying the transmurality of the ablation lesion. The invention pertains to a device for and method of real time monitoring of lesion formation as ablation is being carried out.

A dilation instrument and method of imaging an anatomy within a patient includes a dilation catheter having a catheter body, a fluid conduit extending along the catheter body, a dilator, and at least one ultrasonic transducer. The catheter body is configured to distally extend from an instrument body and move relative to the instrument body. The dilator is connected to the catheter body in fluid communication with the fluid conduit and configured to receive a fluid from the fluid conduit and thereby inflate from a contracted state to an expanded state. The at least one ultrasonic transducer positioned on the catheter body and configured to electrically connect to an ultrasonic generator. The at least one ultrasonic transducer is configured to emit a source ultrasonic signal toward an anatomy within a patient for producing a diagnostic or a therapeutic effect.

A method for using metastable perfluorocarbon nanodroplets for ultrasonic lysis of blood clots includes administering metastable perfluorocarbon nanodroplets into a blood vessel that includes or that leads to a blood vessel that includes a blood clot, the metastable perfluorocarbon nanodroplets each have a liquid core comprising a perfluorocarbon material that has a boiling point below 25 C. at atmospheric pressure and that remains stable in liquid form at 25 C. at atmospheric pressure. The method further includes applying ultrasound energy to the perfluorocarbon nanodroplets within or surrounding the blood clot, causing the perfluorocarbon nanodroplets to vaporize and convert to bubbles, which cavitate and lyse the blood clot.

A process for heat treating biological tissue includes repeatedly applying a pulsed energy to a target tissue over a period of time so as to controllably raise a temperature of the target tissue to create a therapeutic effect to the target tissue without destroying or permanently damaging the target tissue. After the first treatment is concluded the application of the pulsed energy to the target tissue is halted for an interval of time. Within a single treatment session a second treatment is performed on the target tissue after the interval of time by repeatedly reapplying the pulsed energy to the target tissue so as to controllably raise the temperature of the target tissue to therapeutically treat the target tissue without destroying or permanently damaging the target tissue.

A process for heat treating biological tissue includes repeatedly applying a pulsed energy to a target tissue over a period of time so as to controllably raise a temperature of the target tissue to create a therapeutic effect to the target tissue without destroying or permanently damaging the target tissue. After the first treatment is concluded the application of the pulsed energy to the target tissue is halted for an interval of time. Within a single treatment session a second treatment is performed on the target tissue after the interval of time by repeatedly reapplying the pulsed energy to the target tissue so as to controllably raise the temperature of the target tissue to therapeutically treat the target tissue without destroying or permanently damaging the target tissue.

Methods for treating and managing pain in a patient with therapeutic neuromodulation and associated systems and methods are disclosed herein. Chronic or debilitating pain can be associated, for example, with a disease or condition of the abdominal or reproductive viscera. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a target blood vessel of a diseased or damaged organ of a patient experiencing pain. Targeted sympathetic nerve activity can be modulated at least along afferent pathways which can improve a measurable parameter associated with the pain of the patient The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

A catheter system for imparting pressure to induce fractures in a vascular lesion within or adjacent a vessel wall, includes a catheter and a superheating system. The catheter can advance to the vascular lesion. The catheter includes an elongate shaft and a balloon coupled to the elongate shaft. The balloon includes a balloon wall. The balloon moves between a collapsed configuration and a first expanded configuration suitable for anchoring the catheter in position relative to a treatment site. The superheating system can heat a balloon fluid within the balloon rapidly enough to achieve spontaneous vaporization of the balloon fluid and to generate inertial bubbles and acoustic pressure waves. The superheating system can include a first light guide extending along the elongate shaft. The first light guide is in optical communication with a light source at a proximal portion of the first light guide. The first light guide can include a first light window at a distal portion of the first light guide. The first light guide can be an optical fiber and the light source can be a laser.

Disclosed herein is a therapeutically active agent usable in the treatment of pulmonary arterial hypertension (PAH), for use in the treatment of pulmonary arterial hypertension, as well as methods of treating PAH, said treatment and methods comprising administering such an active agent and effecting pulmonary artery denervation in the subject. In some aspects, a sub-therapeutically effective amount of the active agent is administered. In some aspects, the method is devoid of administering such an active agent for at least one month subsequent to the denervation. Further disclosed is a method of treating PAH comprising determining a responsiveness of the subject to at least one therapeutically active agent usable in treating PAH; and effecting pulmonary artery denervation in a subject responsive to the active agent(s).

Methods, systems, devices, assemblies and apparatuses for treatment of hypertension in a patient using renal denervation. The therapeutic assembly includes an energy delivery element. The energy delivery element is configured to provide renal denervation energy to a nerve within a blood vessel of a patient. The therapeutic assembly includes a controller. The controller is coupled to the energy delivery element. The controller is configured to determine that the hypertension in the patient is orthostatic. The controller is configured to apply renal denervation energy to the patient using the energy delivery element.